Christina Wenglén

Company: Anamar

Job title: Head of Research

Seminars:

Integrating Therapeutic Platform with Biomarkers & Genetic Analysis for Novel Targets that Mitigate the Heterogenous Nature of Fibrotic Diseases 2:30 pm

Exploring the unique dual action of AM1476’s and its potential addresses the heterogeneous nature of systemic sclerosis and other fibrotic indications Investigating AnaMar’s integration of their therapeutic platform with biomarkers and genetic analysis to enhance the precision and efficacy of AM1476 Using novel genetic marker approaches using a gene signature to identify responders to treatmentRead more

day: Day One